May 30, 2013
DURHAM, N.C. – Novan Therapeutics, today announced results from a recent clinical trial demonstrating that nitric oxide releasing drug candidate SB204 reduces colonization of the acne causing bacteria Propionibacterium acnes (P. acnes) in the skin of healthy volunteers.
March 6, 2013
DURHAM, N.C. — Novan Therapeutics has closed on $11 million in financing as the company heads into clinical trials studying a potential new acne treatment.
February 28, 2013
DURHAM, N.C. – Novan Therapeutics, a clinical-stage drug development company, today announced in vitro and animal testing data indicating that the company’s drug candidate, SB204, could lead to a topical treatment to reduce oil production in the skin.